US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Virtus LifeSci Biotech Products ETF

109.66

+2.292.13%

Post-market: 109.660.00000.00%16:10 EDT

Volume:13.30K

Turnover:1.44M

Market Cap:120.62M

PE:- -

High:109.83

Open:109.80

Low:107.61

Close:107.37

52wk High:110.05

52wk Low:68.05

Shares:1.10M

Float Shares:1.10M

Volume Ratio:1.49

T/O Rate:1.21%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Regeneron’s dupilumab granted orphan drug designation

Celcuity announces FDA approval of Revtorpyk

Caris Life Sciences expands prostate cancer offering with PTEN IHC testing

Nexalis Therapeutics Options Expire Unexercised, Streamlining Capital Structure

Nexalis Therapeutics Issues Over 4.1 Million Unquoted Performance Rights

BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s

Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment

Actinogen Medical Announces Employee Share Scheme Buy-Back

Island Pharmaceuticals Issues Unquoted Options Under Employee Incentive Scheme

Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS

Genetic Technologies Faces ASX Deadlines Amid Long-Term Trading Suspension

ECB Officials Couldn't Overlook Energy Shock in June

Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus

MT Newswires Live

ECB Officials Couldn't Look Through Energy Shock in June

Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis

Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients

Yomiuri: MUFG to Evolve into Growth-oriented Approach, CEO Says

South Korea Anticipates Record Biopharmaceutical Exports for First Half of Year

ImageneBio appoints Matt Robbins as general counsel

HANXBIO-B Forges Strategic Alliance to Pioneer AI-Enhanced Drug Discovery Framework

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/BBP/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BBP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","market":"US","secType":"STK","nameCN":"Virtus LifeSci Biotech Products ETF","latestPrice":109.655,"timestamp":1788379200000,"preClose":107.3666,"halted":0,"volume":13298,"hourTrading":{"tag":"盘后","latestPrice":109.655,"preClose":109.655,"latestTime":"16:10 EDT","volume":9,"amount":986.895,"timestamp":1788379804764,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.021313890912071313,"floatShares":1100004,"shares":1100004,"eps":0,"marketStatus":"Not Yet Opened","change":2.2884,"latestTime":"09-02 16:00:00 EDT","open":109.7996,"high":109.83,"low":107.61,"amount":1442515,"amplitude":0.020677,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788422400000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":107.3666,"sharesOutstanding":600004,"nav":107.332,"aum":118065366.59,"bidAskSpread":0.002354,"postHourTrading":{"tag":"盘后","latestPrice":109.655,"preClose":109.655,"latestTime":"16:10 EDT","volume":9,"amount":986.895,"timestamp":1788379804764,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.492681,"impliedVol":0.2323,"impliedVolPercentile":0.5317},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BBP\",,,,,undefined,":{"symbol":"BBP","floatShares":1100004,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.492681,"shares":1100004,"dividePrice":0,"high":109.83,"amplitude":0.020677,"preClose":107.3666,"low":107.61,"week52Low":68.046,"pbRate":"--","week52High":110.05,"institutionHeld":0,"latestPrice":109.655,"eps":0,"divideRate":0,"volume":13298,"delay":0,"ttmEps":0,"open":109.7996,"prevYearClose":79.9149,"prevWeekClose":105.9199,"prevMonthClose":106.46,"prevQuarterClose":96.2686,"fiveDayClose":108.6574,"twentyDayClose":96.8774,"sixtyDayClose":84.0972},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BBP\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BBP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BBP\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BBP\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2651484502","title":"Regeneron’s dupilumab granted orphan drug designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2651484502","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651484502?lang=en_us&edition=fundamental","pubTime":"2026-07-15 05:05","pubTimestamp":1784063112,"startTime":"0","endTime":"0","summary":"Regeneron’s (REGN) dupilumab was granted FDA orphan drug designation, according to a post on the agency’s website. Published first on TheFly – the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/regenerons-dupilumab-granted-orphan-drug-designation-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/regenerons-dupilumab-granted-orphan-drug-designation-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0882574055.USD","LU0109394709.USD","LU0823416689.USD","LU1917777945.USD","LU2023250504.SGD","LU1974910355.USD","LU2468319806.SGD","BK4139","LU0823434583.USD","REGN","LABU","LU2362541513.USD","BK4588","BBP","LU2089984988.USD","LU0058720904.USD","IBBQ","LU2362541273.HKD","BK4585","LU0053666078.USD","LU2237438978.USD","LU0889565916.HKD","LU0320765992.SGD","LU0823434740.USD","LU2106854487.HKD","LU2362540622.SGD","IBB","LU0289739699.SGD","BBH","LU0114720955.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651655484","title":"Celcuity announces FDA approval of Revtorpyk","url":"https://stock-news.laohu8.com/highlight/detail?id=2651655484","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651655484?lang=en_us&edition=fundamental","pubTime":"2026-07-15 04:55","pubTimestamp":1784062511,"startTime":"0","endTime":"0","summary":"Celcuity (CELC) announced that the U.S. Food and Drug Administration approved REVTORPYK for the treatment of patients with hormone receptor positiv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/celcuity-announces-fda-approval-of-revtorpyk-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/celcuity-announces-fda-approval-of-revtorpyk-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","SYNB","RSPH","BK4585","BBP","CELC","MRNX","FRTY","IYH","PSCH","PINK","LABU","BK4139","BMED","BK4588","MRNY","MEDI","GDOC","TECB","IBB","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651105407","title":"Caris Life Sciences expands prostate cancer offering with PTEN IHC testing","url":"https://stock-news.laohu8.com/highlight/detail?id=2651105407","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651105407?lang=en_us&edition=fundamental","pubTime":"2026-07-14 20:35","pubTimestamp":1784032510,"startTime":"0","endTime":"0","summary":"Caris Life Sciences (CAI) will offer in-house PTEN immunohistochemistry, or IHC, testing following the recent FDA approval of a biomarker-guided th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/caris-life-sciences-expands-prostate-cancer-offering-with-pten-ihc-testing-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/caris-life-sciences-expands-prostate-cancer-offering-with-pten-ihc-testing-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SYNB","LFSC","BK4092","CAI","BK4588","IDNA","IYH","MRNX","BK4139","MRNY","MEDI","GDOC","PINK","FRTY","BK4585","IHC","BK4162","PSCH","BBP","RSPH","PTEN","BMED","IBB","LABU","TECB","BK4104"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651612476","title":"Nexalis Therapeutics Options Expire Unexercised, Streamlining Capital Structure","url":"https://stock-news.laohu8.com/highlight/detail?id=2651612476","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651612476?lang=en_us&edition=fundamental","pubTime":"2026-07-14 13:27","pubTimestamp":1784006857,"startTime":"0","endTime":"0","summary":"InhaleRx Limited ( ($AU:NX1) ) just unveiled an announcement. Nexalis Therapeutics Ltd, an ASX-listed biotechnology company trading under the ticke...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-options-expire-unexercised-streamlining-capital-structure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-options-expire-unexercised-streamlining-capital-structure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","FHLC","AGNG","XT","BK4588","BK4539","JDOC","BK4139","DARP","FWD","BBP","RSPH","LENZ","SYNB","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651247371","title":"Nexalis Therapeutics Issues Over 4.1 Million Unquoted Performance Rights","url":"https://stock-news.laohu8.com/highlight/detail?id=2651247371","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651247371?lang=en_us&edition=fundamental","pubTime":"2026-07-14 13:27","pubTimestamp":1784006835,"startTime":"0","endTime":"0","summary":"InhaleRx Limited ( ($AU:NX1) ) just unveiled an update. Nexalis Therapeutics Ltd is an Australian-listed biotechnology company focused on developin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-issues-over-4-1-million-unquoted-performance-rights?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nexalis-therapeutics-issues-over-4-1-million-unquoted-performance-rights?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGNG","FHLC","JDOC","BK4007","BK4585","LENZ","BK4588","IBB","DARP","FWD","XT","BK4139","BK4539","BBP","SYNB","RSPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651422771","title":"BioArctic’s Partner Eisai Wins FDA Nod for At-Home Leqembi Injection in Early Alzheimer’s","url":"https://stock-news.laohu8.com/highlight/detail?id=2651422771","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651422771?lang=en_us&edition=fundamental","pubTime":"2026-07-14 06:08","pubTimestamp":1783980525,"startTime":"0","endTime":"0","summary":"BioArctic AB Class B ( ($SE:BIOA.B) ) has shared an update. BioArctic’s partner Eisai has secured U.S. FDA approval for Leqembi Iqlik, a once-weekl...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bioarctics-partner-eisai-wins-fda-nod-for-at-home-leqembi-injection-in-early-alzheimers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bioarctics-partner-eisai-wins-fda-nod-for-at-home-leqembi-injection-in-early-alzheimers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4503","LU0441851309.USD","FRTY","IYH","LU2065170008.USD","MRNX","LU2360107671.USD","SG9999002679.SGD","RSPH","SG9999014492.USD","BMED","BK4585","LABU","PINK","LU0499858438.USD","MEDI","LU0516422366.SGD","BK4588","LU0532188223.SGD","LU0516423091.SGD","SG9999002414.USD","IE0031814969.USD","FDNI","LFSC","LU0823039010.USD","PSCH","LU2125910849.SGD","IBB","LU2152927971.USD","GDOC","LU2065171402.SGD","LU0589944569.HKD","LU0251143029.SGD","HBCP","BK4211","LU1861220207.SGD","MRNY","TECB","BBP","BK4535","BK4220","SG9999014484.SGD","SG9999013478.USD","IDNA","SG9999002406.SGD","SE","SG9999002620.SGD","SYNB","LU0516423174.USD","BK4554"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651144496","title":"Lakefront Biotherapeutics Board Member Resigns After Sanofi R&D Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=2651144496","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651144496?lang=en_us&edition=fundamental","pubTime":"2026-07-14 04:57","pubTimestamp":1783976270,"startTime":"0","endTime":"0","summary":"Lakefront Biotherapeutics ( ($LKFT) ) has provided an update. Lakefront Biotherapeutics, a Belgium-based biotechnology company listed on Euronext a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/lakefront-biotherapeutics-board-member-resigns-after-sanofi-rd-appointment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/lakefront-biotherapeutics-board-member-resigns-after-sanofi-rd-appointment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","FWD","BK4007","XT","IBB","SYNB","BK4588","JDOC","RSPH","FHLC","DARP","SNYNF","AGNG","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651019180","title":"Actinogen Medical Announces Employee Share Scheme Buy-Back","url":"https://stock-news.laohu8.com/highlight/detail?id=2651019180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651019180?lang=en_us&edition=fundamental","pubTime":"2026-07-13 15:38","pubTimestamp":1783928315,"startTime":"0","endTime":"0","summary":"Actinogen Medical ( ($AU:ACW) ) has provided an announcement. Actinogen Medical Ltd., an ASX-listed biotechnology company trading under the ticker ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/actinogen-medical-announces-employee-share-scheme-buy-back-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/actinogen-medical-announces-employee-share-scheme-buy-back-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","RSPH","JDOC","AGNG","BBP","XT","IBB","FHLC","SYNB","DARP","FWD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651196208","title":"Island Pharmaceuticals Issues Unquoted Options Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2651196208","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651196208?lang=en_us&edition=fundamental","pubTime":"2026-07-13 14:33","pubTimestamp":1783924409,"startTime":"0","endTime":"0","summary":"Island Pharmaceuticals Ltd ( ($AU:ILA) ) has provided an announcement. Island Pharmaceuticals Ltd is an Australian-listed biotechnology company foc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/island-pharmaceuticals-issues-unquoted-options-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/island-pharmaceuticals-issues-unquoted-options-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AGNG","RSPH","BK4585","SYNB","BK4588","FHLC","DARP","BBP","IBB","JDOC","FWD","XT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156997423","title":"Insilico Medicine Surges Over 7% in Morning Trading on New AI Drug Discovery Partnership with CMS","url":"https://stock-news.laohu8.com/highlight/detail?id=1156997423","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156997423?lang=en_us&edition=fundamental","pubTime":"2026-07-13 10:10","pubTimestamp":1783908642,"startTime":"0","endTime":"0","summary":"Insilico Medicine (03696) shares rose more than 7% in early trading. At the time of writing, the stock is up 6.21% to HK$45.48, with a turnover of HK$332 million. On July 13th, according to a post on...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGIX","CHAT","AIPO","BBP","IE00BVYPNQ40.USD","VTHR","IE00BVYPNP33.GBP","LU2488822045.USD","00867","QTOC","IE00BMCWC346.EUR","BK1593","IE00BYV24P56.USD","SG9999004220.SGD","LFSC","SG9999015952.SGD","SG9999015978.USD","SG9999015945.SGD","BK4585","BK1191","GSKH","SBIO","BK4588","WRND","IE00BGHQDM52.EUR","PBE","IBB","SG9999015986.USD","GDOC","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650074239","title":"Genetic Technologies Faces ASX Deadlines Amid Long-Term Trading Suspension","url":"https://stock-news.laohu8.com/highlight/detail?id=2650074239","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650074239?lang=en_us&edition=fundamental","pubTime":"2026-07-10 14:52","pubTimestamp":1783666376,"startTime":"0","endTime":"0","summary":"Genetic Technologies ( ($AU:GTG) ) has shared an update. Genetic Technologies Limited, a biotechnology company specializing in genetic testing and ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/genetic-technologies-faces-asx-deadlines-amid-long-term-trading-suspension?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/genetic-technologies-faces-asx-deadlines-amid-long-term-trading-suspension?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HELX","AGNG","DARP","JDOC","BK4585","BBP","FHLC","WDNA","XT","BK4588","IBB","FWD","RSPH","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650927633","title":"ECB Officials Couldn't Overlook Energy Shock in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2650927633","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650927633?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:41","pubTimestamp":1783604460,"startTime":"0","endTime":"0","summary":"The European Central Bank said it was unable to overlook the energy shock at its meeting in June, when higher energy prices were expected to push inflation above its 2% target over the medium term.The","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UCC","AVIE","FXD","CLIX","HIDV","DECU","FXR","TXUE","BBP","IDEV","LCG","CMCI","CDC","DFUV","ILCV","IJK","ARP","IMOM","KOMP","CGDV","GSG","CMDT","HGER","LGH","MAPP","PRVS","EES","VAW","FLV","IMCG","ADPV","BAMA","DIVZ","BKDV","AVDV","CGUS","FXL","PEVC","IUS","BKCI","MDLV","CAOS","ANEW","AVSD","FT","MODL","EQRR","CGUI","BSR","BGH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650593922","title":"Teva Pharmaceuticals Obtains Rights to Commercialize Polpharma's Biosimilar Candidate to Ocrevus","url":"https://stock-news.laohu8.com/highlight/detail?id=2650593922","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650593922?lang=en_us&edition=fundamental","pubTime":"2026-07-09 21:09","pubTimestamp":1783602548,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  Teva Pharmaceuticals International subsidiary and Polpharma Biologics said Thursday they have signed a global licensing agreement that gives Teva exclusive rights to commercialize Polpharma's proposed biosimilar to multiple sclerosis drug Ocrevus.The licensing agreement covers both the intravenous and subcutaneous formulations of Polpharma's biosimilar candidate, the companies said.Under the agreement, Polpharma Biologics will be responsible for the development and manufacturing of the biosimilar candidate, while Teva will be tasked with regulatory submissions and subsequent commercialization in the US, Europe, Brazil, Canada, Australia, New Zealand, Israel, and Turkey, according to a statement.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","BK4585","BK4588","BK4007","BK4596","BK4584","BBP","BK4559","LU2324357040.USD","LU1983299246.USD","TEVA","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650924226","title":"ECB Officials Couldn't Look Through Energy Shock in June","url":"https://stock-news.laohu8.com/highlight/detail?id=2650924226","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650924226?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:55","pubTimestamp":1783601700,"startTime":"0","endTime":"0","summary":"The European Central Bank said it was unable to overlook the energy shock at its meeting in June, when higher energy prices were expected to push inflation above its 2% target over the medium term.The","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSDD","TSLG","CRSH","07366","TSLR","UCC","HGER","07766","CAOS","ANEW","IUS","FXL","TLA","TSLQ","TSYY","AVSD","TSII","KOMP","TSLZ","TSLP","CGDV","TSL","TSLI","TSLL","IDEV","TXUE","BKCI","09366","AVIE","AVDV","FXR","TSLY","CMCI","TSLW","PEVC","TESL","IMOM","CMDT","VAW","BGH","DFUV","BBP","TSLO","GSG","IJK","EQRR","TSLT","CLIX","TSLS","TEST"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650492491","title":"Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2650492491","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2650492491?lang=en_us&edition=fundamental","pubTime":"2026-07-09 20:30","pubTimestamp":1783600200,"startTime":"0","endTime":"0","summary":"Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus (ocrelizumab), including both intravenous and subcutaneous formulations. Agreement advances T","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/09/3324800/0/en/Teva-and-Polpharma-Biologics-Announce-Global-Licensing-Agreement-for-a-Biosimilar-Candidate-to-Ocrevus-ocrelizumab-for-Multiple-Sclerosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649999887","title":"Satellos Bioscience Posts Encouraging Six-Month TRAILHEAD Data in Adult DMD Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2649999887","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649999887?lang=en_us&edition=fundamental","pubTime":"2026-07-08 18:57","pubTimestamp":1783508255,"startTime":"0","endTime":"0","summary":"The latest update is out from Satellos Bioscience ( ($TSE:MSCL) ). Satellos Bioscience Inc., a clinical-stage biotechnology company developing the ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/satellos-bioscience-posts-encouraging-six-month-trailhead-data-in-adult-dmd-patients?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/satellos-bioscience-posts-encouraging-six-month-trailhead-data-in-adult-dmd-patients?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DARP","RSPH","BBC","FHLC","IBB","SYNB","FWD","BK4585","BBP","BK4588","JDOC","AGNG","XT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649996223","title":"Yomiuri: MUFG to Evolve into Growth-oriented Approach, CEO Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2649996223","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649996223?lang=en_us&edition=fundamental","pubTime":"2026-07-08 17:58","pubTimestamp":1783504680,"startTime":"0","endTime":"0","summary":"Mitsubishi UFJ Financial Group Inc.  will \"evolve into a growth-oriented approach\" and \"convert challenges into tangible results,\" said President and Group CEO Junichi Hanzawa during an interview with The Yomiuri Shimbun.Hanzawa leads the new management team of the Japanese financial group. The following is excerpted from the interview.The Yomiuri Shimbun: You assumed the post of president  on April 1. What themes are you focusing on?Hanzawa: We need to transform our business portfolio. The area of asset management and investor services is particularly important. It currently accounts for only about 5%-6% of operating profit, so there is still room for growth. We aim to raise that figure to double digits in the future. We are also considering mergers and acquisitions in the United States, or in t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GABF","KCE","ROE","BBP","BK4207","MUFG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141237651","title":"South Korea Anticipates Record Biopharmaceutical Exports for First Half of Year","url":"https://stock-news.laohu8.com/highlight/detail?id=1141237651","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141237651?lang=en_us&edition=fundamental","pubTime":"2026-07-08 13:23","pubTimestamp":1783488181,"startTime":"0","endTime":"0","summary":"Data released by the South Korean government on Wednesday indicates that the country's biopharmaceutical exports for the first half of this year are projected to reach a record high.According to...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MRNY","MRNX","BBP","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649938286","title":"ImageneBio appoints Matt Robbins as general counsel","url":"https://stock-news.laohu8.com/highlight/detail?id=2649938286","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649938286?lang=en_us&edition=fundamental","pubTime":"2026-07-07 21:16","pubTimestamp":1783430160,"startTime":"0","endTime":"0","summary":"ImageneBio (IMA) announced the appointment of Matt Robbins as general counsel, effective July 7. Robbins joins the clinical-stage biotechnology com...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/imagenebio-appoints-matt-robbins-as-general-counsel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/imagenebio-appoints-matt-robbins-as-general-counsel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DARP","FHLC","BK4585","RSPH","SYNB","IMA","JDOC","FWD","BK4007","XT","BBP","IBB","BK4588","AGNG","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173871150","title":"HANXBIO-B Forges Strategic Alliance to Pioneer AI-Enhanced Drug Discovery Framework","url":"https://stock-news.laohu8.com/highlight/detail?id=1173871150","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173871150?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:12","pubTimestamp":1783422743,"startTime":"0","endTime":"0","summary":"HANXBIO-B has announced a strategic partnership aimed at harnessing the power of artificial intelligence to revolutionize the drug development process.The company has entered into a formal agreement...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","PBE","ARTY","BK1173","BK4585","QTOC","SBIO","VTHR","WRND","BBP","GSKH","BK4588","CHAT","AIPO","BK1161","AGIX","GDOC","LFSC","03378","IBB"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":6,"totalSize":130,"code":"91000000","status":"200"}]}}